Skip to main content
. 2012 Oct 15;17(8):1053–1065. doi: 10.1089/ars.2012.4518

FIG. 7.

FIG. 7.

Simultaneous abrogation of Casp8ap2 and Pdcd10 has a stronger cytoprotection in PCMSC. (A–C) Western blot and densitometry analysis showing the successful abrogation of CASP8AP2, PDCD10 and the simultaneous abrogation of CASP8AP2/PDCD10 in PCMSC after the pretreatment of cells with siRNA specific for Casp8ap2 and Pdcd10. The pretreatment with Sc siRNA did not change the Casp8ap2, Pdcd10 in PCMSC (PCx2). Non-PCMSC were used as a baseline control. (D) LDH release was significantly reduced in PCMSC (two cycles 30 min A/R; PCx2) pretreated with Casp8ap2, Pdcd10, and Casp8ap2/Pdcd10 siRNA as compared with the Sc siRNA-transfected PCMSC after 6 h of anoxia. Non-PCMSC were used as a baseline control.